Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 2/2013

01-04-2013 | Evolving Therapies (RM Bukowski, Section Editor)

Custirsen (OGX-011): Clusterin Inhibitor in Metastatic Prostate Cancer

Authors: Sohaib Al-Asaaed, Eric Winquist

Published in: Current Oncology Reports | Issue 2/2013

Login to get access

Abstract

Adenocarcinoma of the prostate is the most common cancer in men in the Western Hemisphere. This diagnosis includes a clinicopathologically diverse collection of disease entities, encompassing a spectrum from early localized disease to advanced-stage castration-sensitive and ultimately metastatic, castration-resistant states. Although early-stage disease is treatable and potentially curable, treatment options for castration-resistant prostate cancer, the common pathway to prostate cancer death, remain limited and palliative in nature. Therapeutic resistance to androgen blockade, cytotoxic chemotherapy, and radiotherapy is underpinned by a number of cellular mechanisms. The upregulation of protective, antiapoptotic chaperone proteins is one of these mechanisms, and is exemplified by the protein clusterin in castration-resistant prostate cancer. Antisense oligonucleotide technology provides the potential to inhibit specific genes in cancer cells and with this the possibility of a vast impact in oncology, but no antisense drugs have been approved for use in cancer patients to date. Custirsen (OGX-011) is a novel antisense oligonucleotide drug which targets clusterin expression, and its application in prostate cancer is reviewed in this article.
Literature
1.
Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. European Urol. 2012;61(6):1079–92.CrossRef
2.
Di Lorenzo G, Buonerba C, Autorino R, De Placido S, Sternberg CN. Castration-resistant prostate cancer: current and emerging treatment strategies. Drugs. 2010;70(8):983–1000.PubMedCrossRef
3.
Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19(8):1893–907.PubMedCrossRef
4.
Gleave M, Miyake H, Chi K. Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer. Cancer Chemother Pharmacol. 2005;56:47–57.PubMedCrossRef
5.
Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14(6):1756–64.PubMed
6.
Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12.PubMedCrossRef
7.
Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–20.PubMedCrossRef
8.
de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels J-P, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–54.PubMedCrossRef
9.
de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005.PubMedCrossRef
10.
Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–97.PubMedCrossRef
11.
Parker C, Heinrich D, O'Sullivan JM, Fossa SD, Chodacki A, Demkow T, et al. Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. J Clin Oncol 30, 2012 (suppl 5; abstr 8).
12.
Galletti E, Magnani M, Renzulli ML, Botta M. Paclitaxel and docetaxel resistance: molecular mechanisms and development of new generation taxanes. Chem Med Chem. 2007;2(7):920–42.PubMed
13.
Seruga B, Tannock IF. Chemotherapy-based treatment for castration-resistant prostate cancer. J Clin Oncol. 2011;29(27):3686–94.PubMedCrossRef
14.
Cortes JE, Pazdur R. Docetaxel. J Clin Oncol. 1995;13(10):2643–55.PubMed
15.
Sissung TM, Baum CE, Deeken J, Price DK, Aragon-Ching J, Steinberg SM, et al. ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. Clin Cancer Res. 2008;14(14):4543–9.PubMedCrossRef
16.
Bouchet BP, Galmarini CM. Cabazitaxel, a new taxane with favorable properties. Drugs Today (Barc). 2010;46(10):735–42.CrossRef
17.
Zoubeidi A, Chi K, Gleave M. Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clinical Cancer Res. 2010;16(4):1088–93.CrossRef
18.
Miyake H, Nelson C, Rennie PS, Gleave ME. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Res. 2000;60(9):2547–54.PubMed
19.
Miyake H, Hara I, Gleave ME, Eto H. Protection of androgen-dependent human prostate cancer cells from oxidative stress-induced DNA damage by overexpression of clusterin and its modulation by androgen. Prostate. 2004;61(4):318–23.PubMedCrossRef
20.
Yamanaka K, Rocchi P, Miyake H, Fazli L, So A, Zangemeister-Wittke UWE, et al. Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes. BJU Int. 2006;97(6):1300–8.PubMedCrossRef
21.
Gleave ME, Miyake H, Zellweger T, Chi K, July L, Nelson C, et al. Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer. Urology. 2001;58(2, Suppl 1):39–48.PubMedCrossRef
22.
Rizzi F, Bettuzzi S. The clusterin paradigm in prostate and breast carcinogenesis. Endocr Relat Cancer. 2010;17(1):R1–R17.PubMedCrossRef
23.
Shannan B, Seifert M, Leskov K, Willis J, Boothman D, Tilgen W, et al. Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer. Cell Death Differ. 2006;13(1):12–9.PubMedCrossRef
24.
Calero M, Rostagno A, Matsubara E, Zlokovic B, Frangione B, Ghiso J. Apolipoprotein J (clusterin) and Alzheimer's disease. Microsc Res Tech. 2000;50(4):305–15.PubMedCrossRef
25.
Rosenberg ME, Silkensen J. Clusterin and the kidney. Exp Nephrol. 1995;3(1):9–14.PubMed
26.
Rizzi F, Bettuzzi S. Targeting clusterin in prostate cancer. J Physiol Pharmacol. 2008;59 Suppl 9:265–74.PubMed
27.
Rizzi F, Caccamo AE, Belloni L, Bettuzzi S. Clusterin is a short half-life, poly-ubiquitinated protein, which controls the fate of prostate cancer cells. J Cell Phys. 2009;219(2):314–23.CrossRef
28.
Pucci S, Bonanno E, Pichiorri F, Angeloni C, Spagnoli LG. Modulation of different clusterin isoforms in human colon tumorigenesis. Oncogene. 2004;23(13):2298–304.PubMedCrossRef
29.
Zhang Q, Zhou WEI, Kundu S, Jang TL, Yang X, Pins M, et al. The leader sequence triggers and enhances several functions of clusterin and is instrumental in the progression of human prostate cancer in vivo and in vitro. BJU Int. 2006;98(2):452–60.PubMedCrossRef
30.
Zhang H, Kim JK, Edwards CA, Xu Z, Taichman R, Wang C-Y. Clusterin inhibits apoptosis by interacting with activated Bax. Nat Cell Biol. 2005;7(9):909–15.PubMedCrossRef
31.
Bettuzzi S, Davalli P, Davoli S, Chayka O, Rizzi F, Belloni L, et al. Genetic inactivation of apoJ/clusterin: effects on prostate tumourigenesis and metastatic spread. Oncogene. 2009;28(49):4344–52.PubMedCrossRef
32.
Zellweger T, Kiyama S, Chi K, Miyake H, Adomat H, Skov K, et al. Overexpression of the cytoprotective protein clusterin decreases radiosensitivity in the human LNCaP prostate tumour model. BJU Int. 2003;92(4):463–9.PubMedCrossRef
33.
Steinberg J, Oyasu R, Lang S, Sintich S, Rademaker A, Lee C, et al. Intracellular levels of SGP-2 (clusterin) correlate with tumor grade in prostate cancer. Clin Cancer Res. 1997;3(10):1707–11.PubMed
34.
July LV, Akbari M, Zellweger T, Jones EC, Goldenberg SL, Gleave ME. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate. 2002;50(3):179–88.PubMedCrossRef
35.
Gleave ME, Zellweger T, Chi K, Miyake H, Kiyama S, July L, et al. Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer. Invest New Drugs. 2002;20(2):145–58.PubMedCrossRef
36.
37.
Crooke ST. Molecular mechanisms of action of antisense drugs. Biochim Biophys Acta. 1999;1489(1):31–44.PubMedCrossRef
38.
Chi KN, Gleave ME. Antisense approaches in prostate cancer. Expert Opin Biol Ther. 2004;4(6):927–36.PubMedCrossRef
39.
Gleave M, Miyake H, Zangemeister-Wittke U, Jansen B. Antisense therapy: current status in prostate cancer and other malignancies. Cancer Metastasis Rev. 2002;21(1):79–92.PubMedCrossRef
40.
Miyake H, Hara I, Gleave ME. Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic. Int J Urol. 2005;12(9):785–94.PubMedCrossRef
41.
Zellweger T, Miyake H, Cooper S, Chi K, Conklin BS, Monia BP, et al. Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2'-O-(2-methoxy)ethyl chemistry. J Pharmacol Exp Ther. 2001;298(3):934–40.PubMed
42.
Miyake H, Nelson C, Rennie PS, Gleave ME. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res. 2000;60(1):170–6.PubMed
43.
Miyake H, Tolcher A, Gleave ME. Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model. Cancer Res. 1999;59(16):4030–4.PubMed
44.
Sowery RD, Hadaschik BA, So AI, Zoubeidi A, Fazli L, Hurtado-Coll A, et al. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. BJU Int. 2008;102(3):389–97.PubMedCrossRef
45.
Zellweger T, Chi K, Miyake H, Adomat H, Kiyama S, Skov K, et al. Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin Cancer Res. 2002;8(10):3276–84.PubMed
46.
•• Chi KN, Eisenhauer E, Fazli L, Jones EC, Goldenberg SL, Powers J, et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst. 2005;97(17):1287–96. This is an elegant translational proof-of-principle study demonstrating efficacy of custirsen in human prostate cancer in vivo.PubMedCrossRef
47.
Chi KN, Siu LL, Hirte H, Hotte SJ, Knox J, Kollmansberger C, et al. A phase I study of OGX-011, a 2’-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin Cancer Res. 2008;14(3):833–9.PubMedCrossRef
48.
• Chi KN, Hotte SJ, Yu EY, Tu D, Eigl BJ, Tannock I, et al. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28(27):4247–54. There was improved overall survival with addition of custirsen therapy to docetaxel therapy in this randomized phase II trial.PubMedCrossRef
49.
Saad F, Hotte S, North S, Eigl B, Chi K, Czaykowski P, et al. Randomized phase II trial of custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG Trial P-06c. Clin Cancer Res. 2011;17(17):5765–73.PubMedCrossRef
50.
A phase II study of OGX-011 given prior to radical prostatectomy in patients with localized prostate cancer (NCT00138918). ClinicalTrials.gov. Accessed 15 Nov 2012.
51.
Comparison of docetaxel/prednisone to docetaxel/prednisone in combination with OGX-011 in men with prostate cancer (SYNERGY) (NCT01188187). ClinicalTrials.gov. Accessed 15 Nov 2012.
52.
Comparison of cabazitaxel/prednisone alone or in combination with custirsen for 2nd line chemotherapy in prostate cancer (AFFINITY) (NCT01578655). ClinicalTrials.gov. Accessed 15 Nov 2012.
53.
A study evaluating the pain palliation benefit of adding custirsen to docetaxel retreatment or cabazitaxel as second line therapy in men with metastatic castrate resistant prostate cancer (mCRPC) (NCT01083615). ClinicalTrials.gov. Accessed 15 Nov 2012.
54.
OGX-011 and docetaxel in treating women with locally advanced or metastatic breast cancer (NCT00258375). ClinicalTrials.gov. Accessed 15 Nov 2012.
55.
A study of OGX-011/gemcitabine/platinum-based regimen in stage IIIB/IV non-small cell lung cancer (NSCLC) (NCT00138658). ClinicalTrials.gov. Accessed 15 Nov 2012.
56.
A multinational, randomized, open-label study of custirsen in patients with advanced or metastatic (stage IV) non-small cell lung cancer (NCT01630733). ClinicalTrials.gov. Accessed 15 Nov 2012.
Metadata
Title
Custirsen (OGX-011): Clusterin Inhibitor in Metastatic Prostate Cancer
Authors
Sohaib Al-Asaaed
Eric Winquist
Publication date
01-04-2013
Publisher
Current Science Inc.
Published in
Current Oncology Reports / Issue 2/2013
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-012-0285-1

Other articles of this Issue 2/2013

Current Oncology Reports 2/2013 Go to the issue

Evolving Therapies (RM Bukowski, Section Editor)

Tasquinimod: A Novel Angiogenesis Inhibitor–Development in Prostate Cancer

Evolving Therapies (RM Bukowski, Section Editor)

Enzalutamide, a Second Generation Androgen Receptor Antagonist: Development and Clinical Applications in Prostate Cancer

Head and Neck Cancers (EY Hanna, Section Editor)

Efficacy of Neck Dissection in the Management of Isolated Nodal Recurrence after Head and Neck Cancer Treatment

Gastrointestinal Cancers (BG Czito, Section Editor)

Anal Cancer: Are We Making Progress?

Evolving Therapies (RM Bukowski, Section Editor)

Cabozantinib as a Novel Therapy for Renal Cell Carcinoma

Evolving Therapies (RM Bukowski, Section Editor)

Regorafenib (BAY 73–4506): Stromal and Oncogenic Multikinase Inhibitor with Potential Activity in Renal Cell Carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits